Grainne O'Kane
@graokane
Followers
2K
Following
13K
Media
130
Statuses
841
Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦
Joined August 2013
ABBV-400;Temab-A;c-MET targeting ADC (TOPO1i payload) #PDAC ➡️all pretreated pts ➡️ORR 24% ; ⬆️post GnP v mFFX🤔40% v15% Small no. Or real? ➡️tissue mod/high exp c-met ➡️more efficacy data to come ➡️AEs manageable, nausea + haem ⭐️Exciting potential new tx #ESMO25 @OncoAlert
0
5
13
CASSANDRA trial PAXG vs mFFX Resectable and borderline resectable #PDAC #ESMO25 @OncoAlert ➡️reporting second randomization 4 mths vs 6mths chemo ➡️no diff in EFS ✅improved N0 rates; CA19,9 decline More data to follow , if responding I prefer to give more upfront!
0
8
14
⭐️ZASB-neoGOLP #CCA #ESMO25 Neo Gem/ox/len/toripalimab vs sx + capecitabine ➡️high risk icca : 5cm, vascular involvement, nodes, high ca19.9, multifocal ✅median FU 16.9mth: mEFS 18 vs 8.7mths ➡️ORR 55% mPR 19% ⭐️def of high risk in iCCA -NAC + IO has a role !! @OncoAlert
0
6
9
ABC-HCC #HCC #ESMO25 ➡️Atezo/bev v tace ➡️majority intermediate stage ➡️primary endpt time to failure tx strategy ➡️interim results favouring atezo/bev ⭐️14.6 vs 9.5 mths .. MDTs about to get more interesting @OncoAlert ? How heterogenous were the B pts Full study results
0
6
13
TALENTOP⭐️locally advanced HCC Atezo/Bev induction followed by continued AB vs surgery #HCC #ESMO25 @OncoAlert ➡️95% MVI maj vp1-3 ➡️90% hep b❗️ ➡️TTF 20mths vs 12 mth HR 0.6 Suggests approach possible in select patients; imp of bringing back to mdt
0
7
14
Irish connections #ESMO25 presidential dinner from Medical school @UCC to UAE, Beaumont & St James’s hospital to @pmcancercentre & @TheChristieNHS @LizzySmyth1 @graokane
1
2
20
Presidential dinner #ESMO25 ❤️Catching up with friends All things precision 🎯and HPB @CentralParkWMD receiving ⭐️Best in show💫🏆 @BenWestphalen @niamhjcoleman
0
5
47
First positive Phase 3 trial in the perioperative setting for HCC #ESMO25 ! ✂️💊 The concomitant Lancet publication says it all 🗞️ However: -15% BCLC C -Adj TACE? -Why the MPR 50%? -Only a minority completes the adjuvant -Crossover to camre/rivo also for intrahepatic relapse?
1
8
17
Unfortunately another negative triplet #HCC ➡️ IMbrave152/SKYSCRAPER-14 Atezo/bev/ tiragolumab (anti-tigit) v.atezo/bev ➡️mPFS 8.3 vs 8.2; HR OS 0.94 ➡️more toxicity However in this triplet - little activity evident ; need understand tigit role #esmo2025 @OncoAlert @ILCAnews
0
13
34
HRS-4642: KRAS G12D specific inh ➡️30 pts with first-line GnP ➡️ORR 63% ➡️87% >|=grade 3 AEs - most haem ‼️imp for trial design of combos ?sequencing ? Maintenance ➡️ctDNA role emerging ? Adaptive designs #esmo2025 #PDAC @OncoAlert
1
15
40
GFH375: KRAS G12Di targets both ‘on’ & ‘off’ states #PDAC #ESMO2025 @OncoAlert ➡️68% >|= 2 lines tx ➡️ORR 41%; mPFS 5.6mths ➡️mOS NR; most AEs grade 1/2 ➡️ctDNA - high rates KRAS(not~90%), low tumour suppressor rates
2
24
68
Local options #CCA💫#ESMO2025 ➡️first -importance of biliary drainage; perc stenting -TESLA trial 👏🏻 ➡️roles for ablation/SBRT/SIRT ➡️refining surgery & transplant criteria ➡️can we bring the pump to Europe ✅Exciting time for systemic &LRT/surgery, Superb @BasGrootKoerkam
1
5
17
Comprehensive overview of treatment sequencing in #HCC #ESMO2025👏🏻 ➡️how to choose IO options first-line ➡️TKI choices second-line, limited data and difficulties in accessing treatments ➡️importance of pt factors at MDT ➡️biomarkers still a huge unmet need @DrAngelaLamarca
2
10
29
Amazing overview and visionary talk of Grainne O’Kane on ctDNA in pancreatic cancer. #esmo2025
0
4
16